Type 1 diabetes at a crossroads

Diabetes Care

Volumn 38, Issue 6, 2015, Pages 968-970

  Cefalu, William T ^a   Tamborlane, William V ^b   Skyler, Jay S ^c  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY;

BLOOD GLUCOSE MONITORING; DISEASE COURSE; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE SYSTEM; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET TRANSPLANTATION; PATHOGENESIS; PROPHYLAXIS; RISK REDUCTION; SCREENING TEST;

EID: 84962434215     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0615     Document Type: Editorial

References (15)

1. Cambridge Dictionaries Online. Be at a crossroads. Available from http://dictionary.cambridge.org/us/dictionary/british/be-at-a-crossroads#translations. Accessed 21 March 2015.
2. Dall T, Yang W, Halder P, et al. The economic burden of elevated blood glucose levels in 2012: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes. Diabetes Care 2014;37:3172-3179.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38:140-149.
4. Delahanty LM, Pan Q, Jablonski KA, et al.; Diabetes Prevention ProgramResearch Group. Effects of weight loss, weight cycling, andweight lossmaintenance on diabetes incidence and change in cardiometabolic traits in the Diabetes Prevention Program. Diabetes Care 2014;37:2738-2745.
5. Diabetes Prevention Program Research Group. HbA1c as a predictor of diabetes and as an outcome in the Diabetes Prevention Program: a randomized clinical trial. Diabetes Care 2015;38:51-58.
6. Hsu WC, Araneta MRG, Kanaya AM, Chiang JL, Fujimoto W. BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. Diabetes Care 2015;38:150-158.
7. Cefalu WT, Riddle MC. SGLT2 inhibitors: The latest "new kids on the block"! Diabetes Care 2015;38:352-354.
8. Miller KM, Foster NC, Beck RW, et al.; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015;38:971-978.
9. Atkinson MA, von Herrath M, Powers AC, Clare-Salzler M. Current concepts on the pathogenesis of type 1 diabetesdconsiderations for attempts to prevent and reverse the disease. Diabetes Care 2015;38:979-988.
10. Bonifacio E. Predicting type 1 diabetes using biomarkers. Diabetes Care 2015;38:989-996.
11. Skyler JS. Prevention and reversal of type 1 diabetesdpast challenges and future opportunities. Diabetes Care 2015;38:997-1007.
12. Bell KJ, Smart CE, Steil GM, Brand-Miller JC, King B, Wolpert HA. Impact of fat, protein, and glycemic index on postprandial glucose control in type 1 diabetes: implications for intensive diabetes management in the continuous glucose monitoring era. Diabetes Care 2015;38: 1008-1015.
13. Choudhary P, Rickels MR, Senior PA, et al. Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia. Diabetes Care 2015;38:1016-1029.
14. Robertson RP. Islet transplantation for type 1 diabetes, 2015: what have we learned from alloislet and autoislet successes? Diabetes Care 2015;38:1030-1035.
15. Kowalski A. Pathway to artificial pancreas systems revisited: moving downstream. Diabetes Care 2015;38:1036-1043.